Biopharma Roivant's Q2 income from operations misses

Roivant Sciences

10/11/2025 12:14

Overview

Roivant Q2 revenue declines, missing analyst expectations for income from operations

Company maintains strong cash position of $4.4 bln, supporting cash runway into profitability

Brepocitinib Phase 3 study in dermatomyositis shows significant improvement over placebo

Outlook

Roivant plans NDA filing for brepocitinib in DM in H1 2026

Immunovant expects TED study results in H1 2026

Result Drivers

Research and development (R&D) expenses increased by $21.5 million to $164.6 million for the three months ended September 30, 2025, compared to $143.1 million for the three months ended September 30, 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
$1.57 mln
Q2 EPS
-$0.17
Q2 Net Income
-$166.04 mln
Q2 Income From Operations
Miss
-$306.23 mln
-$278.40 mln (7 Analysts)
Q2 Operating Expenses
$307.80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Roivant Sciences Ltd is $20.50, about 0.6% below its November 7 closing price of $20.62

Press Release: ID:nGNX9SlRMC

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)